- Fate Therapeutics (NASDAQ:FATE -11%) Q2 results: Revenues: $0; Net Loss: ($6.1M) (-9.6%); Loss Per Share: ($0.30) (+93.3%); Quick Assets: $42.0M (-22.2%).
- Financial guidance: existing quick assets and net proceeds from the first tranche of the SVB debt facility will be sufficient to fund operations through 2015.
Fate Therapeutics Q2 results
Recommended For You
More Trending News
About FATE Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| FATE | - | - |
| Fate Therapeutics, Inc. | ||